Srinivasan, Venkataramanujan; Pandi-Perumal, Seithikurippu R.; Moscovitch, Adam; Spence, Warren; Trakht Ilya; Brown, Gregory M.; Cardinali, Daniel P.

Potential use of melatonergic drugs in analgesia: mechanisms of action

Preprint del documento publicado en Brain Research Bulletin 81 362-371; 2010

Este documento está disponible en la Biblioteca Digital de la Universidad Católica Argentina, repositorio institucional desarrollado por la Biblioteca Central “San Benito Abad”. Su objetivo es difundir y preservar la producción intelectual de la institución.

La Biblioteca posee la autorización del autor para su divulgación en línea.

Cómo citar el documento:

Se citará la versión editada:

Potential use of melatonergic drugs in analgesia: mechanisms of action

Venkataramanujam Srinivasan PhD
Sri Sathya Sai Medical Educational and Research Foundation, Prsanthi Nilayam, Plot-40 Kovai Thirunagar, Coimbatore-641014, INDIA
Phone number: +91-9486826359
sainivasan@yahoo.com

Seithikurippu R. Pandi-Perumal MSc
Somnogen Inc,
New York, NY 11418, USA.
Phone number 647-832-6177
sleepresearch@gmail.com

Adam Moscovitch, MD, fRCPC, DABSM, DABfM,
1 Codsel Avenue, Toronto, ON M3H 3V6, CANADA.
Phone number 416-291-0927
adam.moscovitch@csisleep.com

D. Warren Spence, MA,
1 Codsel Avenue, Toronto, ON M3H 3V6, CANADA.
Phone number 416-291-0927
dwspence@fastmail.fm

Ilya Trakht, PhD
Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons of Columbia University,
630 West 168th Street - Rm # BB813,
New York 10032, USA.
Phone number 212-305-7728
it8@columbia.edu

Gregory M. Brown MD, PhD
Professor Emeritus, Department of Psychiatry, University of Toronto
100 Bronte Rd., Unit 422, Oakville, Ontario, CANADA L6L 6L5
Phone number 905-465-2941
gbrownpn@yahoo.ca

D.P. Cardinali MD PhD
Director, Department of Teaching & Research,
Faculty of Medical Sciences,
Short Title: Melatonin and analgesia

Abstract

Melatonin is a remarkable molecule with diverse physiological functions. Some of its effects are mediated by receptors while other, like cytoprotection, seem to depend on direct and indirect scavenging of free radicals not involving receptors. Among melatonin’s many effects, its antinociceptive actions have attracted attention. When given orally, intraperitoneally, locally, intrathecally or through intracerebroventricular routes, melatonin exerts antinociceptive and antiallodynic actions in a variety of animal models. These effects have been demonstrated in animal models of acute pain like the tail-flick test, formalin test or endotoxin-induced hyperalgesia as well as in models of neuropathic pain like nerve ligation. Glutamate, gamma-aminobutyric acid, and particularly, opioid neurotransmission have been demonstrated to be involved in melatonin’s analgesia. Results using melatonin receptor antagonists support the participation of melatonin receptors in melatonin’s analgesia. However, discrepancies between the affinity of the receptors and the very high doses of melatonin needed to cause effects in vivo raise doubts about the uniqueness of that physiopathological interpretation. Indeed, melatonin could play a role in pain through several alternative mechanisms including free radicals scavenging or nitric oxide synthase inhibition. The use of melatonin analogs like the MT$_1$/MT$_2$ agonist ramelteon, which lacks free radical scavenging activity, could be useful to unravel the mechanism of action of melatonin in analgesia. Melatonin has a promising role as an analgesic drug that could be used for alleviating pain associated with cancer, headache or surgical procedures.

Keywords
Nociception – Analgesia – Melatonin – Melatonin analogs - Opioid receptors - Melatonin receptors - Allodynia - Neuropathic pain
Introduction

Melatonin (N-acetyl-5-methoxytryptamine) has been characterized as a remarkable molecule with diverse physiological functions, including the control of circadian rhythms [6,78], sleep regulation [17], enhancement of immunological functioning [22,84], free radical scavenging and antioxidant effects [119,139], inhibition of oncogenesis [15,134], mood regulation [106], vasoregulation [35] and regulation of seasonal reproductive activity [80,121]. Among that broad range of effects attributed to melatonin, its role in analgesia emerges as important because of its clinical implications.

Several early studies in mice [16,29,68,73], hamsters [114], rats [11,92,115,125] and man [33] showed that there is a circadian rhythm in pain perception. Furthermore, the pain threshold rhythm as measured by the tail flick test or by the hot plate test is abolished in the rat either by functional pinealectomy by light [11,12,66] or by surgical pinealectomy [11]. Oral melatonin replacement in a physiological dosage reproducing the baseline 24 h rhythm of 6-sulphatoxymelatonin output restored the rhythm in both pressure-induced and heat-produced nociception that is abolished by light suppression [65,66]. Thus there is evidence that there is a physiologic antinociceptive effect of melatonin driving a circadian rhythm in pain perception. The antinociceptive effect of pharmacological doses of melatonin has therefore been examined in several animal models of pain perception (Table 1).

The pain modulatory role of melatonin has been also explored in human subjects [19,23-25,46,54,63,89,94,97,100,109,112,113,118,135]. The purpose of this review is to discuss the pharmacological basis for the antinociceptive role of melatonin and its analogs and the possible mechanisms by which they cause analgesia. For a recent review on the modulatory role of melatonin in pain see [5].

Melatonin biosynthesis, metabolism and receptors

In all mammals circulating melatonin is synthesized primarily in the pineal gland [26]. In addition, melatonin is also locally synthesized in various cells, tissues and organs including lymphocytes [20], human and murine bone marrow [28], the thymus [101], the gastrointestinal tract [18], skin [133] and, except in humans and rhesus monkeys, in the eyes [83]. In these tissues melatonin seems to play either an autocrine or paracrine role.

Tryptophan serves as the precursor for the biosynthesis of melatonin [1]. It is taken up from the blood and is converted into serotonin via 5-hydroxytryptophan. Serotonin is then acetylated to form N-acetylsertotonin through the action of arylalkylamine N-acetyltransferase (AANAT), one of the key enzymes in melatonin synthesis. N-Acetylsertotonin is then converted to melatonin by hydroxyindole-O-
methyltransferase, which has been identified as a rate-limiting enzyme in the biosynthesis of melatonin [1].

Pineal melatonin biosynthesis is regulated by the light-dark cycle via the retinohypothalamic tract [95]. Special melanopsin-containing retinal ganglion cells [13] project to the suprachiasmatic nucleus of the hypothalamus. Other neuronal circuits include the hypothalamic paraventricular nucleus, the medial forebrain bundle and the reticular formation to influence intermediolateral horn cells of the spinal cord, which are the preganglionic neurons that innervate the superior cervical ganglion (SCG) [96]. The postganglionic fibers that arise from SCG regulate pineal melatonin biosynthesis by releasing norepinephrine (NE) at its pinealocyte receptor sites. NE, by interacting mainly with $\beta_1$-, but also with $\alpha_1$-adrenergic receptors in the pineal gland, activates the adenylyl cyclase-cyclic AMP pathway which in turn regulates expression of enzymes in melatonin biosynthetic pathway [1]. $\alpha_1$-Adrenergic receptors potentiate $\beta$-adrenergic activity by producing a sharp increase in intracellular Ca$^{2+}$ and activation of protein kinase C and of prostaglandin (PG) synthesis [61,72,146]. The subcellular mechanisms involved in the initiation and termination of AANAT activity have been elucidated in great detail (see for ref. [88]). Cyclic AMP stimulates AANAT expression and phosphorylation via protein kinase A, which also allows AANAT to be stabilized by binding of 14-3-3 proteins [47,129]. The nocturnal exposure to bright light suppresses melatonin production immediately by degradation of pineal AANAT [50,70].

Once formed melatonin is not stored within the pineal gland but it diffuses to the blood [141]. In those animals having a deep pineal, like the sheep, melatonin is released into the cerebrospinal fluid (CSF) via the pineal recess to reach high concentrations in the third ventricle, 20 to 30 times higher than that found in the blood [120].

Melatonin in blood is metabolized mainly in the liver where it is hydroxylated in the C6 position by cytochrome P$_{450}$ monooxygenases (CYP450) [26]. It is then conjugated with sulfate to form 6-sulphatoxymelatonin, the main melatonin metabolite found in urine. Melatonin is also deacetylated in neural tissues [57] and is also metabolized to form the kynuramine derivative N$^1$-acetyl-N$^2$-formyl-5-methoxykynuramine (AFMK) [44,58,60]. Interestingly this metabolite shares melatonin’s antioxidant and anti-inflammatory properties [139]. Melatonin is also converted into cyclic 3-hydroxymelatonin in a process that directly scavenges two hydroxyl radicals [139]. Inasmuch as melatonin freely diffuses through all biological membranes, it exerts its actions in almost all cells in the body. Some of its actions are receptor-mediated while many others are receptor-independent.

Membrane-bound melatonin (MT$_1$, MT$_2$) receptors have been identified and cloned from several tissues in the body [37]. These receptors belong to the superfamily of G-protein coupled receptors that
contain the typical 7 transmembrane domains [122]. Activation of melatonin receptors in general leads to a decrease in cyclic AMP concentration. A third melatonin binding site, described initially as the “MT\textsubscript{3} receptor”, has since been identified as quinone reductase 2 [103].

The distribution of melatonin receptors in lamina I-V and lamina X of the spinal cord was demonstrated by autoradiography [108]. By using reverse polymerase chain reaction techniques, transcripts of both MT\textsubscript{1} and MT\textsubscript{2} melatonin receptors have been identified in both ventral and dorsal horns of the lumbar and thoracic regions of the spinal cord of rats [160]. It was thus hypothesized that melatonin exerts its analgesic effects through activation of melatonin receptors present in both spinal cord as well as in various brain regions.

A combination of reagents derived from the molecular clones and pharmacologic tools have revealed a considerable amount of information about the MT\textsubscript{1} and MT\textsubscript{2} receptors [8]. Many G protein-coupled receptors (GPCRs), including the MT\textsubscript{1} and MT\textsubscript{2} receptors, exist in living cells as dimers. The relative propensity of the MT\textsubscript{1} homodimer and MT\textsubscript{1}/MT\textsubscript{2} heterodimer formation are similar whereas that of the MT\textsubscript{2} homodimer is 3-4 fold lower [10,32]. It is of interest that the GPR 50 receptor, though lacking the ability to bind melatonin, abolishes high affinity binding of the MT\textsubscript{1} receptor through heterodimerization [76,77]. Thus the GPR50 receptor may have a role in melatonin function by altering binding to the MT\textsubscript{1} receptor.

Structural modifications of melatonin that seem to predispose to antagonist action include removal of the 5-methoxy group (e.g., luzindole, 2-benzyl N-acetyltryptamine) and the 4-phenyl substituted tetralines e.g. 4-phenyl-2-propionamidotetraline (4-P-PDOT) [36]. Luzindole was the first ligand to be identified as a competitive melatonin receptor antagonist and has since been used extensively in the field to validate melatonin receptor action. It is relatively receptor type non-selective (MT\textsubscript{1}/MT\textsubscript{2} affinity ratio = 16/26) and was the first antagonist to be used for demonstrating that melatonin receptors are involved in the inhibition of dopamine release in rabbit retina and in the phase shift of circadian rhythms in rodents [36]. It must be noted that recent data indicate that luzindole is also an effective antioxidant in vitro [91] inhibiting the formation of 2,2´-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid (ABTS) radical cation by 80% at a concentration of 10 µM. Therefore some of the findings with luzindole can be unrelated to melatonin’s actions on receptors.

4P-PDOT was the first available selective MT\textsubscript{2} melatonin receptor antagonist and it has been used in many studies as a pharmacological tool to demonstrate the involvement of the MT\textsubscript{2} receptor type in physiological function (MT\textsubscript{1}/MT\textsubscript{2} affinity ratio = 66/22000). In particular, it was employed to demonstrate the involvement of MT\textsubscript{2} receptors in mediating phase advances of circadian rhythm of neuronal firing in the
SCN circadian clock [62] and in inhibiting dopamine release in retina [38]. There are no published data available regarding actions of MT₁ selective antagonists on native tissues. Other receptor-mediated effects of melatonin may include nuclear binding to transcription factors such as ROR α₁, ROR α₂, and RZR β that belong to the retinoic acid receptor superfamily [21, 45]. Although their affinity is lower than that of the membrane receptors, they may have a role in paracrine and autocrine melatonin effects.

**Pain perception, hyperalgesia and alldynia**

When applied to the skin, muscle or viscera, various thermal or mechanical stimuli, or chemicals liberated from damaged tissues, evoke, besides pain, a constellation of autonomic behaviors, which collectively have been termed nociception. Nociception includes hyperalgesia (augmented sensitivity to painful stimuli) and alldynia (nociceptive responses to normally innocuous stimuli) [53, 64, 126, 127].

Tissue damage or inflammation release a variety of inflammatory mediators including reactive oxygen species (ROS), PGE₂, leukotrienes, bradykinin, substance P, thromboxanes, inflammatory cytokines such as tumor necrosis factor (TNF)-α or interleukin (IL)-1β, nerve growth factor, ATP and adenosine. Some of these agents directly activate nociceptors, while others release local algogenic agents. Algogenic substances sensitize nociceptive neurons, thereby enhancing neuronal excitability in pain transmission pathways and causing primary hyperalgesia.

The transmission of pain sensation by primary afferent fibers which have their central processes in the dorsal horn of the spinal cord has been shown to be influenced by several receptor subtypes. These include opioid (μ and δ), α₂ adrenoceptors, substance P, neurokinin, glutamate (AMPA and NMDA receptors) and neurotransmitters and neuromodulators such as substance P, calcitonin gene-related peptide and neurokinin [53, 64, 93, 126, 127, 147].

Emerging evidence indicates that ROS are involved in chronic pain, including neuropathic and inflammatory pain [27, 81, 128, 137, 140]. Repeated painful stimulation causes an increase of oxidative stress and free radical generation as studied in the cerebral cortex of rats [123] and several studies have confirmed the association between increased free radical generation and hyperalgesia [48, 69, 75, 98, 124, 130, 152]. An exaggerated inflammatory response to tissue injury, neurogenic inflammation, ischemia and reperfusion injuries can all result in excessive production of ROS. Free radicals, in turn, can increase vascular permeability, release neuropeptides (i.e. substance P), enhance inflammation and cause further tissue damage [27, 81, 128, 137, 140]. ROS scavengers reduced pain behavior as well as hyper-responsiveness of spinal dorsal horn neurons [138], although there was little effect once pain was established [87].
Since melatonin and its endogenous metabolites (e.g. AFMK) are potent direct and indirect antioxidants [58,139], some of its analgesic activity may well depend on ROS scavenging. For example, a high dose of melatonin (100 mg/kg) given intraperitoneally (i.p.) to rats for five days brought about analgesic effects and reduced the level of thiobarbituric acid reactive substances (TBARS) in somatosensory cortex previously increased by painful stimulation [111]. Although the possible reason for the persisting increase in TBARS concentration in somatosensory cortex of the rats following the application of painful stimuli remains to be defined, the increasing neuronal metabolism occurring during pain perception could act as a trigger for intensifying the oxidative processes thereby increasing the free radical generation. Alternatively increased generation of kinins during painful stimuli, or activation of AMPA or NMDA receptors during persisting pain, could generate nitric oxide (NO) or peroxynitrite, an effect that can be blocked by melatonin [51]. Based on these considerations, it was suggested that the analgesic effect of melatonin could attributed to its free radical scavenging action [111]. That the nociceptive intensity is directly proportional to the amount of free radical generation has been confirmed in a recent study employing direct electron paramagnetic (spin) resonance, in which generation of free hydroxyl and nitrooxide radicals was demonstrated following the application of nociceptive stimuli, an effect reduced after application of antioxidants [124].

Among the several ROS NO plays a pivotal role in critical actions involving several aspects of peripheral nerve function and disease [128,140]. NO offers important roles in "normal" afferent signaling of pain through the dorsal horn of the spinal cord and in autonomic control through nitricergic innervation. NO is generated during Wallerian degeneration of peripheral nerves following injury that bear on subsequent regenerative events. Through its actions on vasa nervorum, the blood supply to nerves, NO participates in microvascular changes following injury but also has direct roles in axon and myelin breakdown and "clearance" prior to regeneration [128,140]. During such processes, NO contributes to the development of neuropathic pain. Excessive local levels of NO during inflammation may damage axons and growth cones. Low-grade chronic rises in NO may also contribute toward peripheral nerve damage, or neuropathy in diabetes [128,140]. The preventing effect of melatonin on NO-induced damage has been documented in a variety of tissues (see for references [9,43,71]).

Other mechanisms which relate neuronal pathologies and free radicals induced damage have been suggested. It is now recognized that hyperalgesia, allodynia and pain perception all involve activation of glial cells in the spinal dorsal horn [162]. Activation of microglial cells in the dorsal horn in particular promotes neuropathic pain in a variety of nerve injury models such as spinal nerve ligation or dorsal rhizotomy [142]. Activation of microglial cells has been shown to result in the increase of
purine receptors (P2X$_4$, a family of ATP-gated ion channels that are permeable to Ca$^{2+}$) and p38 MAPK receptors. P2X$_4$ receptor expression in the microglia augments progressively following nerve injury and parallels the development of allodynia. Pharmacological blockade of P2X$_4$ receptors or p38 MAPK receptors through the use of intrathecally administered antagonists has been shown to reverse mechanical allodynia, indicating that activation of microglia, P2X$_4$ and p38MAPK receptors are central to allodynia and neuropathic pain following nerve injury [148]. The effects of melatonin on glial cells are manifold and have been studied for years [110,145].

Melatonin’s role in hyperalgesia and allodynia: evidence from animal models

Melatonin’s antinociceptive effect has been demonstrated by using several experimental models in mice and rats (Table 1). Administered through peripheral or central pathways melatonin, or some of its analogs, brought about a dose-dependent antinociception in models of acute [42,55,73,79,99,105,111,136,143,151,153, 154,157,158], inflammatory [7,14,30,41,59,107,116,117,155] and neuropathic pain [4,86,144,149]. In all cases pharmacological amounts of melatonin were needed to produce effects.

Lakin and his co-workers were the first to show that the intraperitoneal (i.p.) administration of melatonin (30 mg/kg) produced antinociceptive effects in mice [73]. Whether melatonin’s analgesic effect was time-dependent was evaluated in mice through the use of the hot plate procedure [55]. It was found that melatonin (20-40 mg/kg, i.p) exerted its maximal analgesic effect when administered in the late evening. Administration of the opiate antagonist naloxone or the central benzodiazepine (BZP) antagonist flumazenil blunted the analgesic response to melatonin, although they did not modify the pain threshold [55]. These blocking agents increased the latency of the hot plate responses induced by diazepam, thus showing that central opioid and BZP receptors are involved in the analgesic response.

In other studies the antinociceptive effect of melatonin was evaluated by using the hot water tail-flick test in rats. Melatonin, when injected intracerebroventricularly (i.c.v.) in three different doses (30, 60 or 120 mg/kg) to groups of rats produced a dose-dependent antinociception [157]. In this study it was found that in rats that had been given larger doses of melatonin (60 or 120 mg/kg), the effective antinociception started 15 min after melatonin administration, reached a peak after 30 min and lasted for 100 min.

Studies in mice of melatonin’s antinociceptive effects showed that these occurred without inducing physical dependence [159]. To elucidate the mechanism of melatonin’s action, i.c.v. injection of naloxone (10 µg) was given. It was found that melatonin’s
antinociceptive action (60 or 120 mg/kg i.p.) was antagonized by i.c.v.
naloxone via an effect that started 10 min after naloxone administration
and lasted for at least 45 min. Since the changes were observed
following the i.c.v. administration of naloxone, it was concluded that the
CNS was the primary site for melatonin’s analgesic effect [157]. In other
studies, melatonin, when administered in doses 1, 5 or 25 mg/kg i.p. or
0.25, 0.5 or 1 mg/kg i.c.v., produced significant increases in tail
withdrawal latencies [79]. The increased latencies, which started 10 min
after melatonin administration, reached the peak at 30 min, and lasted
for more than 70 min. At all doses melatonin potentiated the
antinociceptive actions of deltorphin-1, a δ-opioid agonist, but not of the
μ-opioid agonist endomorphin-1 [79].

Endotoxin-induced hyperalgesia was used as a model for assessing
melatonin’s antinociceptive effects in inflammation. Intraplantar
injection of lipopolysaccharide (LPS) reduced the threshold for
nociceptive stimulus in the tail-flick and hot-plate tests [67]. LPS injection
(5 μg in 50 μl of saline into the hind paws of mice) produced a significant
decrease in the nociceptive threshold in the hot-plate and tail-flick tests,
6 and 10 h after endotoxin injection [116]. Melatonin (5 or 10 mg/kg)
significantly inhibited LPS-induced hyperalgesia at both time intervals.
The attenuation of LPS-induced hyperalgesia by melatonin was not
reversed by naltrexone (4 mg/kg). In vitro experiments showed that
melatonin suppressed TNF-α release by LPS-activated macrophages.
From these findings it was concluded that suppression of TNF-α could be
one of the mechanisms by which melatonin attenuated LPS-induced
hyperalgesia [116].

Electrical stimulation of the tail test is used as one of the models for
evaluating pain perception, as that arising during carrageenan-induced
inflammation in rats [41]. Melatonin (0.5mg or 1 mg/kg, i.p.) displayed
antinociceptive effects after the electrical stimulation in the rat tail test,
increasing the nociceptive thresholds by 29.6% and 39.5% respectively.
Melatonin at a dose of 0.5mg/kg also increased the antinociceptive
effect of indomethacin and reduced the carrageenan-induced edema
in a dose dependent manner thus demonstrating that melatonin has a
significant anti-inflammatory effect [41]. Locally applied melatonin at
paw in a carrageenan-induced paw edema model in rats inhibited the
inflammatory response via an inhibitory effect on expression of NO
synthase [30]. In another model of inflammatory pain melatonin (150—
600 μg/paw) caused a dose-dependent antinociception which was
reversed by the antagonism of the NO-cyclic GMP-protein kinase G-K+
channel pathway [59].

NMDA receptors in the spinal cord play a major role in pain
transmission at the dorsal horn level and they are involved in the
potentiation of nociceptive synaptic transmission in the spinal cord, a
phenomenon known as “wind-up” [64,126,128]. In this process there is a
repetitive increase in the response of dorsal horn neurons due to increase
in the intensity of C-fiber stimulation. Using C-fiber stimulation to initiate the spinal wind-up effect, Laurido et al. found that different doses of melatonin (1.25 mg, 2.5, 5.0 or 10 mg /kg) produced dose-dependent decreases of spinal cord wind-up, with the highest dose resulting in a complete suppression of wind-up activity [74]. The authors suggested that melatonin-induced spinal wind-up may have been due to melatonin’s intracellular influence on NMDA receptor dependent NO generating pathways.

Both the antinociceptive and antiallodynic effects of melatonin have been studied in experimentally-induced diabetic rats [7]. A formalin test was used as a model for evaluation of pain perception. This pain model produced two nociceptive responses. The first phase occurs within 5 min after formalin injection and involves the activation of C-fibers and the release of substance P and bradykinin [132]. The second response begins after a brief quiescent period and is due to activation of NMDA receptors with increased release of Ca$^{2+}$, histamine, PGs and bradykinin [104]. Oral administration of melatonin (150 mg/kg) significantly reduced formalin-induced nociceptive behavior and has antiallodynic effects at 20 and 60 min post-treatment. This study was the first to describe melatonin’s antinociceptive and antiallodynic effects in streptozotocin-injected diabetic rats [7].

Nerve injury results in abnormal pain perception, known as neuropathic pain, which is associated with hyperalgesia and allodynia. The analgesic effects of melatonin on mice subjected to tight ligation of sciatic nerve was studied by using the withdrawal threshold test (for assessing mechanical allodynia) and withdrawal latencies (for assessing thermal analgesia) [144]. Melatonin at the highest doses (120 mg/kg i.p. and 0.1 nmol i.c.v.) reduced paw withdrawal latencies in response to radiant heat stimulation of the injured hind paw compared to corresponding values of normal rats. When mechanical allodynia was tested, neither i.p. nor i.c.v. melatonin had any effect on the withdrawal thresholds to von Frey hairs compared to the respective injection baseline value. From these findings it was concluded that that both i.c.v. and i.p. melatonin injections at high doses block thermal hyperalgesia in neuropathic mice but did not block mechanical allodynia. Co-administration of both L-arginine and naloxone reduced the effects of melatonin suggesting that melatonin’s effect on thermal hyperalgesia was mediated at least in part by the L-arginine-NO-pathway and the opioidergic system [144].

Administration of melatonin into the anterior cingulate cortex contralateral to peripheral nerve injury prevented exacerbation of mechanical allodynia with a concurrent improvement of depression-like behavior in Wistar-Kyoto rats [161]. In the same experimental model the effect of the individual versus combined treatment of melatonin and/or the NMDA receptor antagonist dextromethorphan was assessed [149]. Dextromethorphan alone was effective in reducing thermal hyperalgesia
at three tested doses (15, 30 or 60 mg/kg) and reduced mechanical
alldynia only at high doses (30 or 60 mg/kg). By comparison,
administration of melatonin alone was effective in reducing thermal
hyperalgesia only at the highest dose (120 mg/kg) tested but failed to
reverse allodynia at all three tested doses (30, 60 and 120 mg/kg). The
combined i.p. administration of melatonin (30 mg/kg) and
dextromethorphan (15 mg/kg) effectively reversed both thermal
hyperalgesia and mechanical alldynia indicating that the combination
of melatonin with a NMDA receptor antagonist can be more effective
than either drug alone for the treatment of neuropathic pain [150].

Involvement of melatonin receptors in antinociception

The possibility that melatonin receptors could be involved in
melatonin’s analgesic action was studied by using the unspecific
MT1/MT2 receptor antagonist luzindole [79,86,105,151,155,158] or the
specific MT2 antagonists 4-P-PDOT [4,143,155] and K185 (N-butynoyl-2-
(5,6,7-trihydro-11-methoxybenzo[3,4]cyclohept[2,1-a]indol-13-y1)ethanamine)[7]. Melatonin administration in different doses i.p. (30, 60
or 120 mg/kg) caused antinociception in a dose-dependent manner. It
was found that the i.c.v. injection of 50 µg of luzindole antagonized
completely melatonin’s antinociceptive effect. As a hypothesis it was
proposed that melatonin reduces the excitability of pain transmitting
dorsal horn neurons via hyperpolarization caused through its binding to
membrane melatonin receptors [74].

The possible participation of melatonin receptors in melatonin
induced antiallodynia was assessed in a rat model of neuropathic pain,
i.e., the ligation of L5/L6 spinal nerves [4]. Intrathecal (3-100 µg) or oral
(37.5 - 300 mg/kg) administration of melatonin decreased tactile
alldynia induced by spinal nerve ligation. Intrathecal administration of
luzindole (1-100 µg) significantly diminished in a dose-dependent manner
the antiallodynic effect of melatonin. Similarly oral (0.01-1 mg/kg) or
intrathecal (0.1 -10 µg) administration of the highly selective MT2 receptor
antagonist 4P-PDOT diminished the antiallodynic effect of melatonin.
Subcutaneous (1mg/kg) or intrathecal (0.5-50 µg) treatment with
naltrexone diminished the antiallodynic effect induced by oral or
intrathecal melatonin [4]. These data suggested that MT2 receptors
present in spinal cord and opioid receptors mediate the antiallodynic
effect of melatonin.

The mechanism for antinociceptive and antiallodynic effects of
melatonin were examined in streptozotocin-induced diabetic rats by
using the MT2 receptor blocking agent K185 [7]. It was found that
melatonin’s antinociceptive effects were diminished by prior
administration of K185 (0.2 to 2 mg/kg s.c.). This demonstrated again that
MT2 receptors present in the spinal cord are involved in melatonin-
induced antinociception. The possible participation of δ-opioid receptors
was assessed by using naltrexone (δ receptor antagonist) and 5-guanidinononaltrinole (κ-opioid receptor antagonist). It was found that naltrexone (but not 5-guanidinononaltrinole) partially reduced the melatonin induced antinociception, thus demonstrating the possible participation of δ, but not κ, opioid receptors in the antinociceptive effect of melatonin in diabetic rats [7].

A number of melatonin analogs have been developed which are more potent than melatonin in binding to MT₁ and MT₂ melatonin receptors [49]. Among these, 2-bromomelatonin (substitution with bromine at the 2 indole position of melatonin) has been shown to be 10 times more effective in binding to melatonin receptors [39]. The analgesic properties of 2-bromomelatonin was tested in Sprague-Dawley rats [99]. 2-Bromomelatonin i.p. injected at 30 and 45 mg/kg doses resulted in significant antinociceptive effects as assessed by the loss of response to tail clamping. The loss of response occurred in 100% of rats after 1 and 2 min of a bolus injection of 45 mg/kg of 2-bromomelatonin [99]. The intrathecal administration of 2-bromomelatonin was effective to decrease mechanical nociception an effect blocked by intrathecal naloxone or luzindole injection [105].

The effect of 6-chloromelatonin on capsaicin-induced mechanical allodynia and hyperalgesia was evaluated in Sprague-Dawley rats [143]. Intradermal injection of capsaicin caused long-lasting primary and secondary allodynia [52]. The increase in paw withdrawal frequency induced by capsaicin was significantly reduced or blocked by the prior Intrathecal injection of the melatonin agonist 6-chloromelatonin [143]. The effect of Intrathecal 6-chloromelatonin was blocked by the intrathecal administration of 4P-PDOT.

The effect of pyridomelatonin analogs on the hot plate latency test and acetic acid induced abdominal writhes was evaluated by Elmegeed et al. [42]. The activity of the tricyclic pyrrolo-and pyrido-indole derivatives 3, 5, 9a and 12 was compared with that of melatonin on thermal and visceral pain and inflammation. Hot plate latency was increased by the administration of all the compounds when assessed 1 h or 2 h after administration. Although compounds 3 and 5 were as effective as melatonin, the effect of compound 12 was significantly more prolonged. All these compounds also significantly reduced the number of abdominal writhes induced in mice by i.p. injection of acetic acid [42]. Compounds 5 and 12 were found to be most potent in this aspect, i.e., they inhibited the number of abdominal writhes by 69 and 81% as compared to controls. Compounds 3, 9a and melatonin inhibited the number of abdominal writhes by 24, 41 and 55% respectively. The authors concluded that the pyrrole moiety of the compounds 5 and 12 acts potently as an antinociceptive agent and that fusion of pyrrole ring to melatonin moiety were beneficial in increasing the antinociceptive action [42].
A major question concerning the involvement of melatonin receptors in the analgesic effect of melatonin refers to the doses of melatonin needed to produce effects. Although, as noted in the introduction, there is evidence for a physiologic role of melatonin in modulating the circadian rhythm in nociception, the lowest effective doses employed (in the mg range) result in melatonin blood levels several orders of magnitude above the concentration necessary to activate melatonin receptors. It must be noted, however, that in many cases the effect of melatonin could be blocked by antagonists like luzindole or 4P-PDOT (Table 1).

In view of the very prominent role that ROS have in pain and of the direct and indirect antioxidant activity of melatonin, the possibility that melatonin could via suppression of ROS production should be considered. There is scarce information on the ROS scavenging properties of many of the melatonin analogs studied. One exception is ramelteon, the MT$_1$/MT$_2$ agonist approved by the FDA by its sleep promoting activity in insomnia in the elderly, which has been demonstrated to be ineffective as ROS scavenger [90].

**Melatonin and opioid system in analgesia**

Earlier studies suggested that melatonin exerts its antinociceptive actions by acting through opiate and/or BZP pathways [55,73,136]. Numerous reports have confirmed the interaction between melatonin and the opioid system [34,79]. Interestingly, this interrelationship is manifold: studies of the distribution of opioid receptors have revealed that δ-opioid receptors are the only opioid receptors that are present in maximum concentrations in the pineal gland [3,56]. Through δ-opioid receptors the activity of AANAT is stimulated, being an event responsible for enhancing pineal melatonin production. Moreover, naloxone administration has been found to decrease the nocturnal maximum in pineal melatonin content of rats, thus confirming the physiological role of opioid receptors in vivo in pineal melatonin control [82].

Fluctuations in pain threshold can be correlated with simultaneous fluctuations in plasma β-endorphin immunoreactivity and melatonin release [12]. The antinociceptive effect of melatonin is blunted by the opiate antagonist naloxone [55,73,86,105,136,151,153,157].

Melatonin’s pharmacodynamics during analgesia induction was studied by defining the effects of melatonin receptor agonists and antagonists on the opioid receptor binding and release of endogenous opioids such as β-endorphin. Administration of melatonin causes the release of β-endorphin, a potent opoid in humans [156]. The release of β-endorphin in the periaqueductal gray perfusate of rats after melatonin administration was found to produce a significant increase of pain threshold in these animals, thus suggesting that melatonin influences pain perception via β-endorphin release [156].

13
Shavali et al. explored melatonin’s effect on the opioid system by studying the mechanism through which it increased β-endorphin release from mouse pituitary AtT-20 cells in culture [131]. The authors speculated that melatonin’s antinociceptive action could be due to its binding to opioid receptors subtypes rather than to binding to its own receptors.

Indeed some evidence has been provided that melatonin interacts with the opioid peptides [2,85]. Melatonin is synthesized following acute pain episodes in humans [102], the function of which may be to modulate fluctuations in opioid receptor expression and levels of beta-endorphin [12]. The relationship of melatonin with the opioidergic system is complex and not completely understood, although there is evidence that it has mixed opioid receptor agonist-antagonist activity [40]. Collectively, these findings lend support to the existence of a “melatonin-opioid axis” [12].

Dai et al. used the mouse tail flick test to study the effect of melatonin on the development of antinociceptive tolerance to different types of opioid receptor agonists [31]. The investigators found that melatonin had no inhibitory effect on tolerance induced by μ-opioid receptor agonist (endomorphin 1) but exerted an inhibitory effect on tolerance induced by δ-opioid receptor agonist (deltotrophin). These effects were shown to be antagonized by luzindole. These findings support the conclusion that melatonin interferes with the neural mechanisms involved in the development of tolerance to deltoid opioid analgesia via interaction with melatonin receptors [31].

The antinociceptive action of melatonin (100 mg/kg, i.p.) on glutamate-induced nociception in mice was completely blocked by i.p. pretreatment of animals with the opioid receptor antagonist naloxone (1 mg/kg), the 5-HT²A receptor antagonist ketanserin (1 mg/kg), the dopaminergic D₂ receptor antagonist sulpiride (50 mg/kg), the α₁-adrenoceptor antagonist prazosin, the MT₁/MT₂ receptor antagonist luzindole (0.15 mg/kg) or L-arginine (600 mg/kg) [86]. From their findings the authors concluded that melatonin induces antinociception by interacting with both peripheral and central melatonin receptors through effects modulated by opioidergic, serotonergic, dopaminergic and adrenergic receptors as well as by the L-arginine-nitric oxide pathway.

Other aspects of the mechanism of interaction between melatonin and opioid peptides in pain regulation was investigated by using the tail-flick assay in mice to evaluate the hyperalgesic effect of orphanin FQ/nociceptin (NC), a member of opioid peptide family [151]. Luzindole and naloxone were used to assess the possible mechanisms of pain modulation by melatonin. When mice were co-injected with melatonin i.c.v. (5, 10 or 50 µg/mouse) and NC (10 µg/mouse) there was a complete absence of the hyperalgesic effect. Injection of luzindole or naloxone (10 µg/mice) inhibited the reversal effect on NC-induced hyperalgesia by melatonin. These findings were interpreted to support
the conclusion that melatonin’s reversal of NC-induced hyperalgesia was mediated by melatonin receptors and promotion of the release of β-endorphin [151].

Conclusions

Melatonin has been shown to exert antinociceptive and antiallodynic actions in a variety of experimental models in animals. Induction of pain involves the release of several pro-inflammatory mediators like cytokines and the activation of a number of neurotransmitter receptor sites present both in the spinal cord and brain. A molecule like melatonin that is effective in: (i) controlling the release of pro-inflammatory mediators; (ii) inhibiting the activation of receptors involved in pain perception present at spinal cord; (iii) inhibiting receptor activation in brain regions involved in pain perception; (iv) promoting sleep, can be extremely effective for controlling/inhibiting pain perception. Melatonin fulfills all these criteria and hence for all practical purposes it could serve as an effective drug in controlling pain perception.

The available evidence demonstrates that melatonin exerts these actions by acting through the opioid system perhaps via melatonin receptors present in the spinal cord and in the brain. There is evidence for involvement of the pineal gland and for a modulatory effect of melatonin on the circadian rhythm of nociception. Nonetheless high doses of melatonin are required to produce major analgesic effects. Thus there may be two different mechanisms involved. Perhaps the circadian rhythm of nociception is related to actions on melatonin receptors while the major analgesic effects are due to non-receptor actions. Therefore, the possibility that melatonin could act via a receptor-independent mechanism like suppression of ROS production should be considered. Further studies on MT1/MT2 agonists such as ramelteon, which lacks free radical scavenger properties, could be useful to answer this query.

The potential value of melatonin’s antinociceptive and antiallodynic action can be appreciated by clinical studies undertaken in patients suffering from pain due to inflammation, pain occurring during headache, pain of cancer patients, neuropathic pain and fibromyalgia [19,23-25,46,54,63,89,94,97,100,109,112,113, 118,135]. The animal models of pain perception suggest that melatonin and its analogs have a promising role as a novel antinociceptive therapy.
References


[36] M.L. Dubocovich, M.I. Masana, S. Iacob, D.M. Sauri, Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor, Naunyn Schmiedebergs Arch. Pharmacol. 355 (1997) 365-375.


contributes to pain hypersensitivity following peripheral nerve injury, Glia 45 (2004) 89-95.


<table>
<thead>
<tr>
<th>Type of animal</th>
<th>Pain Model</th>
<th>Dose, administration route</th>
<th>Effect on pain</th>
<th>Other effects</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>Hot-plate test</td>
<td>Melatonin, 30 mg/kg, i.p.</td>
<td>Antinociception</td>
<td>Blocked by i.p. naloxone</td>
<td>[69]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hot-plate and writhing tests</td>
<td>Melatonin, 200 mg/kg, i.p.</td>
<td>Antinociception</td>
<td>Blocked by s.c. naloxone</td>
<td>[127]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hot-plate and writhing tests; electrical caudal stimulation</td>
<td>Melatonin, 50-200 mg/kg, i.p.</td>
<td>Antinociception</td>
<td>Pretreatment with 5 mg/kg melatonin potentiated meperidine- or morphine-induced analgesia</td>
<td>[144]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hot-plate test</td>
<td>Melatonin, 20 or 40 mg/kg, i.p.</td>
<td>Antinociceptive effect in late evening</td>
<td>Blocked by naloxone or flumazenil i.p.</td>
<td>[52]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hot-plate test. Tail-flick test</td>
<td>Melatonin, 40 – 160 mg/kg, i.p.</td>
<td>Dose-dependent antinociception</td>
<td>Blocked by i.p. naloxone. Attenuated by i.p. reserpine or i.p. phentolamine.</td>
<td>[143]</td>
</tr>
<tr>
<td>Rat</td>
<td>Tail-flick test</td>
<td>Melatonin, 30, 60, 120 mg/kg i.p.</td>
<td>Dose-dependent antinociception</td>
<td>Antagonized by i.c.v. naloxone</td>
<td>[147]</td>
</tr>
<tr>
<td>Rat</td>
<td>Tail-flick test</td>
<td>Melatonin, 30, 60 and 120 mg/kg, i.p.</td>
<td>Dose-dependent antinociception</td>
<td>Antagonized by i.c.v. luzindole</td>
<td>[148]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Hot-plate test. Tail-flick test</td>
<td>Melatonin, 5 mg and 10 mg/kg, i.p.</td>
<td>Attenuated central and behavioral LPS-induced hyperalgesia</td>
<td>Not affected by i.p. naltrexone</td>
<td>[110]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Formalin test</td>
<td>Melatonin, 0.1, 5 and 20 mg/kg, i.p.</td>
<td>Absence of antinociceptive effects</td>
<td>Melatonin increased the antinociceptive response to i.p. diazepam or i.p. morphine.</td>
<td>[101]</td>
</tr>
<tr>
<td>Rat</td>
<td>Tail-flick test. Plantar test</td>
<td>Melatonin, 1.5, 10, 30, 60 and 100 mg/kg, i.p.</td>
<td>Antinociceptive effect in both tests at the highest dose</td>
<td>Painful stimuli increased ROS production, an effect inhibited by melatonin</td>
<td>[105]</td>
</tr>
<tr>
<td>Rat</td>
<td>Carrageenan-induced paw inflammation</td>
<td>Melatonin, 0.5 and 1 mg/kg, i.p.</td>
<td>Melatonin enhanced nociceptive threshold</td>
<td>Mel enhanced the anti-inflammatory effect of indomethacin</td>
<td>[41]</td>
</tr>
<tr>
<td>Rat</td>
<td>Loss of response to tail clamp</td>
<td>2 –Bromomelatonin, 15, 30, 45 mg/kg, i.p.</td>
<td>Loss of response to tail-clamping in 100% of rats 1 and 2 min after injection</td>
<td>Loss of righting reflex in 86% of rats at the highest dose (hypnotic effect)</td>
<td>[93]</td>
</tr>
<tr>
<td>Rat</td>
<td>Mechanical nociception</td>
<td>2 –Bromomelatonin, 10µg/10 µl, intrathecally</td>
<td>Time-dependent increase in mechanical nociception</td>
<td>Antagonized by intrathecal naloxone or luzindole</td>
<td>[99]</td>
</tr>
<tr>
<td>Rat</td>
<td>Capsaicin-induced increase in paw withdrawal frequency</td>
<td>Melatonin, 2µg/2µl or 10µg/10 µl intrathecally 6-Chloromelatonin, 1µg/1µl, intrathecally</td>
<td>Reduced the frequency of paw withdrawals</td>
<td>Antagonized by the intrathecal administration of 4P-PDOT</td>
<td>[133]</td>
</tr>
<tr>
<td>Species</td>
<td>Model</td>
<td>Test</td>
<td>Melatonin Dose(s)</td>
<td>Antagonists</td>
<td>Notes</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>------</td>
<td>-------------------</td>
<td>-------------</td>
<td>-------</td>
</tr>
<tr>
<td>Mouse</td>
<td>Tail-flick test</td>
<td>Melatonin, 1, 5, 25 mg/kg, i.p. Melatonin, 0.25, 0.5, 1 mg/kg, i.c.v.</td>
<td>Enhanced antinociception given by delta-opioid agonists but not by mu-opioid agonists</td>
<td>Antagonized by i.c.v. luzindole</td>
<td>[74]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Chemical and behavioral models of pain</td>
<td>Melatonin, 10-100 mg/kg, i.p. Melatonin, 250-500 pmol i.c.v. Melatonin, 30-100 ng/intraplantar</td>
<td>Reduced the neurogenic pain caused by the intraplantar injection of glutamate in dose-dependent manner</td>
<td>The antinociceptive effect of melatonin was completely prevented by pretreatment of animals with naloxone, ketanserin, sulpirideL-arginine, yohimbine and luzindole</td>
<td>[81]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Mechanical allodynia and thermal hyperalgesia after nerve ligation</td>
<td>Melatonin, 30, 60,120 mg/kg, i.p. Melatonin, 0.001, 0.01, 0.1nmol, i.c.v.</td>
<td>With highest doses both i.p (120mg/kg) and i.c.v. (0.1nmol) reduced thermal analgesia but not alldynia</td>
<td>L-arginine and naloxone (i.p. or i.c.v.) reduced the effect of melatonin on thermal hyperalgesia</td>
<td>[134]</td>
</tr>
<tr>
<td>Mouse</td>
<td>Tail-flick test</td>
<td>Melatonin, 5, 10, 50 mg/kg i.p. Melatonin, 5, 10, 50 µg/mouse i.c.v.</td>
<td>Dose-dependent reversion of hyperalgesia caused by i.c.v. administration of orphanin FQ/nociceptin</td>
<td>Effect of melatonin antagonized by i.c.v. naloxone or luzindole</td>
<td>[141]</td>
</tr>
<tr>
<td>Rat</td>
<td>Formalin test</td>
<td>Melatonin, 10-300 mg/kg, p.o.</td>
<td>Antinociceptive and antiallodynic effects seen with a 150 mg/kg or greater dose..</td>
<td>MT(_2) receptor antagonist K185 s.c. blocked melatonin-induced antinociceptive and antiallodynic activity in diabetic rats</td>
<td>[7]</td>
</tr>
<tr>
<td>Rat</td>
<td>Hot-plate test</td>
<td>Melatonin pyrrolo[1,2-α] indole derivatives 3, 5, 12, 14 3, 5, 9a, 12, s.c.</td>
<td>The melatonin pyrrolo[1,2-α] indole derivatives exerted more powerful antinociceptive activity than melatonin. Activity of compounds 5 and 12 was highest</td>
<td>The melatonin pyrrolo[1,2-α] indole derivatives also exhibited significant anti-inflammatory activity</td>
<td>[42]</td>
</tr>
<tr>
<td>Rat</td>
<td>Mechanical allodynia after nerve ligation</td>
<td>Melatonin, 37.5-300 mg/kg p.o. Melatonin, 3-100 µg intrathecally</td>
<td>Dose-dependent anti-allodynia</td>
<td>Antagonized by intrathecally-administered luzindole or orally or intrathecally-administered 4-P-PDOT</td>
<td>[4]</td>
</tr>
<tr>
<td>Rat</td>
<td>Formalin test</td>
<td>Melatonin, (150—600 µg/paw ipsilaterally applied</td>
<td>Dose-dependent antinociception</td>
<td>Antagonized by antagonism of the NO-cyclic GMP-protein kinase G-K⁺ channel pathway</td>
<td>[56]</td>
</tr>
<tr>
<td>Rat</td>
<td>Formalin test</td>
<td>Melatonin, 3, 10 or 30 µg intrathecally</td>
<td>Dose-dependent antinociception</td>
<td>Antagonized by intrathecally-administered luzindole or 4-P-PDOT</td>
<td>[145]</td>
</tr>
<tr>
<td>Rat</td>
<td>Mechanical allodynia and thermal hyperalgesia after nerve ligation</td>
<td>Local administration of melatonin into the contralateral anterior cingulate cortex</td>
<td>Melatonin prevented the exacerbation of mechanical allodynia</td>
<td>A concurrent improvement of depression-like behavior was observed</td>
<td>[151]</td>
</tr>
<tr>
<td>Rat</td>
<td>Mechanical allodynia and thermal hyperalgesia after nerve ligation</td>
<td>Melatonin, 30, 60 ,120 mg/kg, i.p.</td>
<td>Reduced thermal analgesia but not alldynia only with the highest dose</td>
<td>The combined i.p. administration of melatonin (30 mg/kg) and the NMDA receptor antagonist dextromethorphan effectively reversed both thermal hyperalgesia and mechanical allodynia</td>
<td>[139]</td>
</tr>
</tbody>
</table>